Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,236 recruiting studies in this area right now.
By phase
- Not applicable3,144
- Phase 21,066
- Phase 1823
- Phase 1/Phase 2446
- Phase 3426
- Phase 4238
- Phase 2/Phase 393
Top conditions
- Multiple Sclerosis345
- Multiple Myeloma334
- Asthma194
- Lymphoma183
- Rheumatoid Arthritis141
- Type 1 Diabetes131
- Atopic Dermatitis129
- Systemic Lupus Erythematosus126
- Acute Lymphoblastic Leukemia123
- HIV Infections117
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 170
- Hodgkin Lymphoma67
- Leukemia64
- Rheumatoid Arthritis (RA)64
- Mantle Cell Lymphoma62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)91
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- Novartis Pharmaceuticals65
- M.D. Anderson Cancer Center63
- AstraZeneca57
- City of Hope Medical Center46
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California492
- Maryland196
- Alabama179
- Arizona141
- Florida141
- New York122
- Massachusetts120
- Texas119
- Illinois82
- Colorado77
Recruiting studies6,236 total
- NCT06980480RecruitingPhase 3
Gammagard to prevent infections in multiple myeloma
This study tests if adding Gammagard (a type of antibody therapy) to your multiple myeloma treatment with Tecvayli can help prevent serious infections. You may qualify if you recently started Tecvayli and are still responding to it.
Mobile, AlabamaAges 18 years+ - NCT06948318RecruitingPhase 3
Follow-up study of mezagitamab for chronic ITP
This study follows up with adults who completed a previous mezagitamab trial for chronic immune thrombocytopenia (ITP). It monitors long-term safety and effectiveness of the treatment.
Hot Springs, ArkansasAges 18 years+ - NCT07638735Enrolling by invitation
Greener asthma inhaler prescribing tool
This study tests a tool that helps doctors choose asthma inhalers that are better for the environment. It may help your clinic reduce its carbon footprint while keeping your patients' asthma well managed.
Toronto, OntarioAges 16 years+ - NCT06722235RecruitingPhase 3
Mezagitamab for chronic ITP that hasn't responded to standard treatments
This study tests a new medicine called mezagitamab for adults with chronic ITP (low platelets for at least a year) who have not responded well to standard treatments. It aims to see if mezagitamab can safely raise platelet counts.
Hot Springs, ArkansasAges 18 years+ - NCT07409454RecruitingPhase 2
Post-transplant treatment for multiple myeloma with a bispecific antibody
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
TianjinAges 18 years+ - NCT07498335RecruitingPhase 3
Atrasentan for children with IgA nephropathy
This trial tests an experimental medicine called atrasentan for children aged 2 to under 18 with IgA nephropathy, a kidney disease. The study aims to see if the drug can help protect kidney function and reduce protein in the urine, with fewer side effects than current treatments.
Neptune City, New JerseyAges 2–18 - NCT06973811RecruitingPhase 2
ZR-MTX for Newly Diagnosed Eye Lymphoma
This trial tests a combination of two drugs, zanubrutinib and methotrexate, for people with a newly diagnosed lymphoma that affects only the eyes. The goal is to see if this treatment works well and is safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT07235384RecruitingPhase 1
Zai Lab tests ZL-1503 for moderate to severe eczema
This study tests a new medication called ZL-1503 for people with moderate to severe atopic dermatitis (eczema) that hasn't improved enough with topical treatments. The trial will check if the drug is safe and how well it works.
Woolloongabba, QueenslandAges 18–65 - NCT06575374RecruitingPhase 2
Letermovir to prevent CMV after CAR T-cell therapy
This trial tests if a drug called letermovir can safely prevent CMV (a common virus) from reactivating after you receive CAR T-cell therapy (Axi-cel). It may help reduce infections and side effects.
Houston, TexasAges 18 years+ - NCT07606352RecruitingPhase 2
STL303 Safety and Efficacy for IgA Kidney Disease
This trial tests a new drug called STL303 for patients with IgA nephropathy, a type of kidney disease where IgA (an antibody) builds up and damages kidneys. The study aims to see if STL303 is safe and can help slow kidney damage in people whose current blood pressure medications alone aren't controlling their protein loss.
Woolloongabba, QueenslandAges 18 years+ - NCT05752500Recruiting
Behavior coaching to help older adults with HIV move more
This study tests a tailored behavioral coaching program to increase physical activity in adults age 50+ who have HIV and are currently not very active. It may help you build safer, more routine movement using a Fitbit for tracking.
Minneapolis, MinnesotaAges 50 years+ - NCT03773965RecruitingPhase 3
Baricitinib study for kids with juvenile arthritis
This study tests baricitinib, a medicine, in children and teens with juvenile idiopathic arthritis. It includes only families who already took baricitinib in an earlier study and did not stop it permanently or develop an allergy.
RosarioAges 1–18 - NCT06471257RecruitingPhase 3
Study of PT027 vs PT007 in Chinese Adults with Asthma
This study tests a new combination inhaler (budesonide/albuterol) against another asthma inhaler in adults whose asthma is not well controlled on their current medications. It aims to see if the new inhaler can reduce serious asthma attacks and improve symptoms.
BaotouAges 18 years+ - NCT07642557Recruiting
Real-world remibrutinib use for chronic hives in Germany
This study observes how remibrutinib (a newer medication) works for chronic hives (CSU) when prescribed in routine clinical practice in Germany. Remibrutinib is used when standard allergy medications don't work well enough. The study tracks your symptoms and treatment over 24 months to understand how well it helps real patients.
DürenAges 18 years+ - NCT06565078Recruiting
Safety study of immune globulin for primary immunodeficiency
This study is a safety check for people with primary immunodeficiency who are already using a specific immune globulin treatment given under the skin. It looks at medical records to see if any side effects occurred.
Tokyo, TokyoAges Any age - NCT06687551RecruitingPhase 4
Testing lower doses of JAK inhibitors for rheumatoid arthritis
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Toulouse, OccitanieAges 18–65 - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT06733935RecruitingPhase 1/Phase 2
Study of NKX019 for immune diseases
This trial tests an investigational cell therapy called NKX019 for people with certain autoimmune diseases like scleroderma, myositis, vasculitis, or rheumatoid arthritis. It aims to see if NKX019 can help control the disease when standard treatments have not worked well enough.
Orange, CaliforniaAges 18–75 - NCT06890884RecruitingPhase 2
Comparing two drug combos for untreated DLBCL
This trial tests a new drug, zilovertamab vedotin, added to standard chemo, compared with another approved drug combo for people with untreated DLBCL (a type of lymphoma). It aims to see which is more effective.
Mobile, AlabamaAges 18 years+ - NCT06136559RecruitingPhase 3
Study of Nemtabrutinib vs ibrutinib or acalabrutinib for untreated CLL/SLL
This trial tests a new drug, nemtabrutinib, against two standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment yet. The goal is to see if the new drug works better at controlling the disease.
Mobile, AlabamaAges 18 years+ - NCT03135886Recruiting
Testing for HIV in opioid treatment programs
This project studies how to improve offering and completing HIV (and hepatitis C) tests in opioid treatment programs. It may help increase timely follow-up and linkage to care when results are positive.
New York, New YorkAges 18 years+ - NCT06620679Recruiting
Brain inflammation and stress in healthy men
This study explores how inflammation in the body affects the brain's response to stress. Healthy men will have brain scans and stress tests to understand this link better.
Leuven, Flemish BrabantAges 18–45 - NCT06275477Recruiting
Gallium-68 FAPI-46 PET/CT for inflammation and fibrosis
This trial uses a special PET/CT scan with a tracer called 68Ga-FAPI-46 to see if it can better detect inflammation and scarring (fibrosis) in people with chronic diseases like scleroderma, pulmonary fibrosis, or rheumatoid arthritis. The goal is to improve diagnosis and monitoring.
BrestAges 18 years+ - NCT06252402RecruitingEarly Phase 1
CAR T cells for HIV: A new immunotherapy study
This trial tests a new type of immune cell, called a CAR T cell, that is designed to target and kill cells infected with HIV. It may help control the virus without needing to take HIV medication all the time.
Duarte, CaliforniaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,236 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,675 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.